Skip to main content
Erschienen in: Endocrine 1/2016

05.05.2016 | Editorial

Reassessing the grade of gastroenteropancreatic neuroendocrine neoplasms

verfasst von: David S. Klimstra

Erschienen in: Endocrine | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Excerpt

In the study by Grillo et al. [1], the authors undertook systematic re-evaluation of gastroenteropancreatic neuroendocrine neoplasms diagnosed before formal grading and staging were routinely performed. They found that reclassification was feasible and of value, as the outcome of the patients strongly correlated with the grade, using the ENETS/WHO grading system. …
Literatur
1.
2.
Zurück zum Zitat W.D. Travis et al., Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am. J. Surg. Pathol. 15(6), 529–553 (1991)CrossRefPubMed W.D. Travis et al., Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am. J. Surg. Pathol. 15(6), 529–553 (1991)CrossRefPubMed
3.
Zurück zum Zitat S.N. Hochwald et al., Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J. Clin. Oncol. 20(11), 2633–2642 (2002)CrossRefPubMed S.N. Hochwald et al., Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J. Clin. Oncol. 20(11), 2633–2642 (2002)CrossRefPubMed
4.
Zurück zum Zitat S. Van Eeden et al., Classification of low-grade neuroendocrine tumors of midgut and unknown origin. Hum. Pathol. 33(11), 1126–1132 (2002)CrossRefPubMed S. Van Eeden et al., Classification of low-grade neuroendocrine tumors of midgut and unknown origin. Hum. Pathol. 33(11), 1126–1132 (2002)CrossRefPubMed
5.
Zurück zum Zitat D.S. Klimstra, Pathologic classification of neuroendocrine neoplasms. Hematol. Oncol. Clin. North Am. 30(1), 1–19 (2016)CrossRefPubMed D.S. Klimstra, Pathologic classification of neuroendocrine neoplasms. Hematol. Oncol. Clin. North Am. 30(1), 1–19 (2016)CrossRefPubMed
6.
Zurück zum Zitat A. Scarpa et al., Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod. Pathol. 23(6), 824–833 (2010)CrossRefPubMed A. Scarpa et al., Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod. Pathol. 23(6), 824–833 (2010)CrossRefPubMed
7.
Zurück zum Zitat D.S. Klimstra et al., Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am. J. Surg. Pathol. 34(3), 300–313 (2010)CrossRefPubMed D.S. Klimstra et al., Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am. J. Surg. Pathol. 34(3), 300–313 (2010)CrossRefPubMed
8.
Zurück zum Zitat Z. Yang, L.H. Tang, D.S. Klimstra, Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am. J. Surg. Pathol. 35(6), 853–860 (2011)CrossRefPubMed Z. Yang, L.H. Tang, D.S. Klimstra, Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am. J. Surg. Pathol. 35(6), 853–860 (2011)CrossRefPubMed
9.
Zurück zum Zitat V. Rebours et al., Can pancreatic neuroendocrine tumour biopsy accurately determine pathological characteristics? Dig. Liver Dis. 47(11), 973–977 (2015)CrossRefPubMed V. Rebours et al., Can pancreatic neuroendocrine tumour biopsy accurately determine pathological characteristics? Dig. Liver Dis. 47(11), 973–977 (2015)CrossRefPubMed
10.
Zurück zum Zitat N. Raj, D. Reidy-Lagunes, Systemic therapies for advanced pancreatic neuroendocrine tumors. Hematol. Oncol. Clin. North Am. 30(1), 119–133 (2016)CrossRefPubMed N. Raj, D. Reidy-Lagunes, Systemic therapies for advanced pancreatic neuroendocrine tumors. Hematol. Oncol. Clin. North Am. 30(1), 119–133 (2016)CrossRefPubMed
11.
Zurück zum Zitat O. Basturk et al., The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am. J. Surg. Pathol. 39(5), 683–690 (2015)CrossRefPubMedPubMedCentral O. Basturk et al., The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am. J. Surg. Pathol. 39(5), 683–690 (2015)CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat L.H. Tang et al., Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin. Cancer Res. 22(4), 1011–1017 (2015)CrossRefPubMed L.H. Tang et al., Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin. Cancer Res. 22(4), 1011–1017 (2015)CrossRefPubMed
13.
Zurück zum Zitat H. Sorbye et al., Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann. Oncol. 24(1), 152–160 (2013)CrossRefPubMed H. Sorbye et al., Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann. Oncol. 24(1), 152–160 (2013)CrossRefPubMed
Metadaten
Titel
Reassessing the grade of gastroenteropancreatic neuroendocrine neoplasms
verfasst von
David S. Klimstra
Publikationsdatum
05.05.2016
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2016
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-0966-x

Weitere Artikel der Ausgabe 1/2016

Endocrine 1/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.